4 Carlson LA, OlssonAG. Intravenous prostaglandin E1 in severe peripheral vascular disease[J].Lancet, 1976, 9(7886)∶810
5 Shindo H,Tawata M,Inoue M,et al.The effect of prostaglandin E1 alphaCD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabeticneuropathy[J].Diabetes Res Clin Pract, 1994, 24(3)∶173～180
7 Toyota T, Hirata Y, Ikeda Y, et al. Lipo-PGE1, a newlipid-encapsulated preparation of prostaglandin E1：placebo-and prostaglandinE1-controlled multicenter trials in patients with diabetic neuropathy and legulcers[J]. Prostaglandins, 1993, 46(5)∶453～468
8 Mizushima Y, Yanagawa A, Hoshi K, et al. prostaglandin E1 is more effective,when incorporated in lipid microspheres, for treatment of peripheral vascular disease inman[J].J Pharm Pharmacol, 1983, 35(3)∶666～667
收稿：2000-02-24修回：2000-05-08
4Ziegler MD,Sohr CG,Nourooz Z,et al.Oxidative stree and anti ox dant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy[J].Diabentic Care,2004,27(9):2178-2183.
5Paul V,Claude LD,Jean LR,et al.A multicenter,double-blind,safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy,a preliminary report[J].Diabetes Complications,2005,19(5):247-253.
